Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antineoplastic agents --- Cancer --- Design. --- Chemotherapy. --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Drugs --- Treatment --- Chemotherapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antineoplastic agents. --- Cancer --- Chemotherapy. --- Antineoplastic agents --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Drugs --- Treatment --- Chemotherapy --- Quimioteràpia del càncer

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Emerging as an important new volume in the renowned Cancer Drug Discovery and Development™ series, Deoxynucleoside Analogs in Cancer Therapy expertly summarizes the current status of development and application of deoxynucleoside analogs. Authoritative up-to-date reviews are presented by scientists well known in their specific areas and all contributions include valuable sound advice on structure and topics. Organized into several sections, the first part covers general aspects of drug uptake and metabolism and explains how novel technology has enabled a rapid expansion of this field. The second part is concerned with a number of specific drugs including cytarabine, gemcitabine, troxacitabine, clofarabine and Ara-G. The final section covers pharmacokinetics, prodrugs, and specific applications such as radiosensitization, gene therapy, and the use of deoxynucleoside analogs as tracers. Throughout Deoxynucleoside Analogs in Cancer Therapy, the focus is on novel aspects of deoxynucleoside analogs in the clinical context, as well as on unexpected targets of these compounds, such as their specific activity against cell cycle-dependent kinases or oncogenes. The wealth of information presented here can be used to design rational combinations aimed at inhibiting various cellular signaling pathways, or combining inhibition of various targets. Deoxynucleoside Analogs in Cancer Therapy has been designed specifically to facilitate such an interaction between various fields.

Deoxyribonucleotides --- Antineoplastic agents. --- Cancer --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Ribonucleotides, Deoxy --- Therapeutic use. --- Chemotherapy. --- Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Drugs --- Nucleotides --- Antineoplastic agents --- Chemotherapy --- Treatment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Regional cancer therapies remain important options in the management of malignant disease, in spite of the venue of more targeted agents for systemic therapies. New te- nologies and better guidance systems for radiofrequency ablation and intrastitial laser therapies, highly selective intravascular approaches with improved catheters and gu- ance systems, improved agents for embolizations, and new vasoactive drugs for isolated limb and liver perfusions are just a few of the new developments in a field that is alive and progressing. Regional Cancer Therapy, so well put together by the editors Peter M. Schlag and Ulrike S. Stein, presents an overview of today’s realities and tomorrow’s possibilities. Regional cancer therapy models provide ways to make new discoveries about tumor biology and new agents that may be used regionally as well as systemically. This book should therefore be of interest to all clinicians and scientists with an interest in tumor biology as well as clinical advances. Alexander M. M. Eggermont, MD, PhD Professor and Head of Surgical Oncology Erasmus University MC—Daniel den Hoed Cancer Center Rotterdam, the Netherlands v PREFACE The treatment of malignant tumors has been substantially improved in recent years due to developments in clinical medicine and technology as well as by advances in mole- lar biological research. Modern molecular and genetic techniques allow the charact- ization of molecules that are decisive for tumor development and progression.

Cancer --- Drug targeting. --- Infusion therapy. --- Antineoplastic agents --- Chemotherapy. --- Administration. --- Drugs --- Site-specific drug delivery --- Targeting of drugs --- Target organs (Anatomy) --- Infusions (Therapeutics) --- Parenteral therapy --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Targeting --- Dosage forms --- Treatment --- Chemotherapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer. Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs. Road map to anticancer drug development from discovery to NDA submission Discussion of molecular targets and preclinical screening Development and validation of bioanalytical methods Chapters on clinical trial design and phase 0, I, II, III clinical trials Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents Review of the drug development process from both laboratory and clinical perspectives New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development.

Antineoplastic Agents -- pharmacokinetics. --- Antineoplastic Agents -- pharmacology. --- Antineoplastic agents -- Research -- Handbooks, manuals, etc. --- Antineoplastic agents. --- Antineoplastic agents --- Therapeutic Uses --- Pharmacologic Actions --- Chemical Actions and Uses --- Chemicals and Drugs --- Antineoplastic Agents --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Research --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Pharmacy. --- Chemistry --- Medicine --- Drugs --- Materia medica --- Pharmacology --- Cancer --- Chemotherapy